These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review. Dell'Osso B; Nestadt G; Allen A; Hollander E J Clin Psychiatry; 2006 Apr; 67(4):600-10. PubMed ID: 16669725 [TBL] [Abstract][Full Text] [Related]
16. A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder. Whalen PJ; Johnstone T; Somerville LH; Nitschke JB; Polis S; Alexander AL; Davidson RJ; Kalin NH Biol Psychiatry; 2008 May; 63(9):858-63. PubMed ID: 17964548 [TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. Davidson JR; DuPont RL; Hedges D; Haskins JT J Clin Psychiatry; 1999 Aug; 60(8):528-35. PubMed ID: 10485635 [TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety, and tolerability of venlafaxine XR in generalized anxiety disorder. Kelsey JE Depress Anxiety; 2000; 12 Suppl 1():81-4. PubMed ID: 11098419 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. Feighner JP; Entsuah AR; McPherson MK J Affect Disord; 1998 Jan; 47(1-3):55-62. PubMed ID: 9476744 [TBL] [Abstract][Full Text] [Related]
20. Mergers and acquisitions among psychotropics: antidepressant takeover of anxiety may now be complete. Stahl SM J Clin Psychiatry; 1999 May; 60(5):282-3. PubMed ID: 10362433 [No Abstract] [Full Text] [Related] [Next] [New Search]